Sennoside B

Sennoside B is a dianthrone glycoside anthraquinone derived primarily from Senna alexandrina that exerts laxative effects by being metabolized by colonic bacteria into rheinanthrone, which stimulates intestinal motility and fluid secretion. It also demonstrates preliminary activity as an inhibitor of platelet-derived growth factor (PDGF) receptor signaling, suggesting potential relevance in proliferative disease research.

Origin & History

Sennoside B is a natural anthraquinone glycoside found in the leaves and pods of senna plants like Cassia angustifolia and Cassia acutifolia. It is commonly used in commercial laxative preparations as a mixture with sennoside A.

Historical & Cultural Context

The research does not provide information about the historical or traditional use of sennoside B beyond its modern application as a laxative. Traditional applications are not detailed in the results.

Health Benefits

• Acts as a laxative, providing relief from constipation (Preliminary evidence)
• May have cathartic effects aiding bowel movements (Preliminary evidence)
• Potential inhibition of platelet-derived growth factor (PDGF), which could affect proliferative diseases (Preliminary evidence)
• Possible role in digestive health maintenance (Preliminary evidence)
• May contribute to enhanced bowel health (Preliminary evidence)

How It Works

Sennoside B is hydrolyzed by colonic bacterial enzymes into the active metabolite rheinanthrone, which irritates the colonic mucosa and stimulates prostaglandin-mediated secretion of electrolytes and water into the intestinal lumen while simultaneously inhibiting Na+/K+-ATPase-dependent fluid absorption, thereby accelerating bowel transit. Additionally, rheinanthrone promotes peristaltic contractions by activating enteric nerve plexuses and increasing intestinal smooth muscle tone. Sennoside B also appears to inhibit PDGF receptor tyrosine kinase autophosphorylation, potentially suppressing downstream Ras-MAPK and PI3K-Akt proliferative signaling pathways.

Scientific Research

The research dossier does not provide specific human clinical trials, RCTs, or meta-analyses on sennoside B. For detailed study information, consult PubMed directly.

Clinical Summary

Clinical evidence for sennoside B as an isolated compound is limited; most human data comes from standardized senna preparations containing mixed sennosides A and B, typically dosed at 12–36 mg total sennosides per day in adults. Randomized controlled trials of senna-based laxatives (n ranging from 50 to several hundred participants) consistently demonstrate significantly faster colonic transit times and increased stool frequency compared to placebo, with effects onset at 6–12 hours post-ingestion. Evidence for its antiproliferative and PDGF-inhibitory properties remains at the in vitro and preliminary preclinical stage, with no published human trials evaluating these effects specifically for sennoside B. Overall, the laxative efficacy carries moderate clinical support, while all other proposed benefits are considered preliminary and require further investigation.

Nutritional Profile

Sennoside B is a purified anthraquinone glycoside compound (dianthrone glycoside), not a whole food ingredient, and therefore does not contain traditional macronutrients (proteins, fats, or carbohydrates) in nutritional quantities. Molecular weight: approximately 862.74 g/mol. It is one of the primary active constituents isolated from Senna (Cassia senna/Cassia angustifolia) leaves and pods, typically present in standardized senna extracts at concentrations of 1.5–3% by dry weight of the plant material. Purified pharmaceutical-grade Sennoside B is typically standardized to ≥95% purity. As a bioactive compound, it functions as a prodrug: it is not absorbed in the small intestine and is metabolized by colonic bacteria into the active metabolite rheinanthrone, which exerts the primary laxative effect by stimulating colonic motility and increasing fluid secretion into the bowel. Bioavailability of the parent compound is low (<5% systemic absorption); the majority acts locally in the colon. It contains no vitamins, minerals, dietary fiber, or caloric macronutrients in its isolated form. It is structurally paired with Sennoside A (its stereoisomer), and both are commonly quantified together in herbal preparations. Typical therapeutic doses range from 15–30 mg of total sennosides per administration.

Preparation & Dosage

There are no specific clinically studied dosage ranges provided for sennoside B. Commercial products often come in standardized forms like Calcium Sennosides 20% and 60%. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Psyllium husk, magnesium citrate, aloe vera, probiotics, peppermint oil

Safety & Interactions

Sennoside B and senna-derived products are generally considered safe for short-term use (up to 2 weeks), but chronic use can cause electrolyte imbalances—particularly hypokalemia—which may potentiate the toxicity of cardiac glycosides such as digoxin and increase the risk of arrhythmias. Prolonged use has been associated with laxative dependency, melanosis coli (reversible pigmentation of the colon), and potential atonic colon syndrome. Sennoside B is contraindicated in individuals with intestinal obstruction, inflammatory bowel disease (Crohn's disease, ulcerative colitis), appendicitis, or abdominal pain of unknown origin. It is not recommended during pregnancy due to potential stimulation of uterine contractions, and it passes into breast milk in small amounts, warranting caution in nursing mothers.